NCT05132660
Treating Early Stage Diabetic Retinopathy
Enrolling by Invitation
EARLY_PHASE1Ages 30–80InterventionalTreatmentVA Office of Research and DevelopmentGovernment-funded
~244 participants
Updated 2026-04-07 on ClinicalTrials.gov
What's tested:Sinemet CRplacebo
At a glance
Recruiting sites
0 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Electroretinogram
Measured over 24 months
Conditions
Where it's being run
1 sites across 1 statesGeorgia1
Study leadership
- Machelle T. Pardue, PhD · PRINCIPAL_INVESTIGATOR · Atlanta VA Medical and Rehab Center, Decatur, GA
Who to contact
This trial hasn't published a contact. View it on ClinicalTrials.gov
Do you actually qualify for this trial?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Eligibility criteria
Inclusion
HbA1c 8-12%
Diabetic patients with no retinopathy as screened with teleretinal imaging
Diabetic patients with microaneurysms as detected with fundus teleretinal screening
ERG oscillatory potential delays in response to dim flash stimuli
Exclusion
Patients with pituitary tumor, psychosis, Parkinson's disease
Patients with confounding ocular disease (visually significant cataract, glaucoma, macular degeneration, retinitis pigmentosa)
Patients with cognitive deficits (score of 24 or less on the Montreal Cognitive
Assessment-MOCA
No anti-VEGF or steroid treatments within the last 12 months
Pregnancy
What this trial measures
- Electroretinogram24 months
Electrical activity of the retina measured by non-invasive electrodes on the face to a flash to light. A waveform will be recorded and timing of the waves measured in milliseconds